Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy

Bibliography

• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-17
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84(2):236-42
   PubMed Web of Science ®Google Scholar
• Xie HG, Zou JJ, Hu ZY, et al. Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther 2011;129(3):267-89
   Google Scholar
• Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94(3):317-23
   PubMed Web of Science ®Google Scholar
• Notarangelo MF, Bontardelli F, Merlini PA. Genetic and nongenetic factors influencing the response to clopidogrel. J Cardiovasc Med (Hagerstown) 2013;14(Suppl 1):S1-7
   Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108(7):2244-7
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 Genotype With the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302(8):849-58
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5(12):2429-36
   PubMed Web of Science ®Google Scholar
• Chae H, Kim M, Koh YS, et al. Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int 2013;2013:154073
   PubMed Web of Science ®Google Scholar
• Chan MY, Tan KR, Tan HC, et al. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 2012;13(5):533-42
   Google Scholar
• Luo HR, Poland RE, Lin KM, et al. Genetic polymorphism of cytochrome P4502C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80(1):33-40
   PubMed Web of Science ®Google Scholar
• Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11(3):199-206
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI A meta-analysis. JAMA 2010;304(16):1821-30
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao XJ, Shin JG, et al. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Kim S, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in east asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ-Cardiovasc Inte 2011;4:585-U98
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm [Last accessed 27 September 2014]
   Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning” a report of the american college of cardiology foundation task force on clinical expert consensus documents and the american heart association. Circulation 2010;122:537-57
   PubMed Web of Science ®Google Scholar
• Reese ES, Mullins CD, Beitelshees AL, et al. Cost-Effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012;32:323-32
   PubMed Web of Science ®Google Scholar
• Panattoni L, Brown PM, Te Ao B, et al. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes a new zealand evaluation. Pharmacoeconomics 2012;30:1067-84
   PubMed Web of Science ®Google Scholar
• Lala A, Berger JS, Sharma G, et al. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost 2013;11:81-91
   PubMed Web of Science ®Google Scholar
• Crespin DJ, Federspiel JJ, Biddle AK, et al. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health 2011;14:483-91
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Horowitz JD, Sorich M, et al. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics 2013;14:2013-21
   PubMed Web of Science ®Google Scholar
• Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med 2014;160:221-32
   PubMed Web of Science ®Google Scholar
• Guzauskas GF, Hughes DA, Bradley SM, et al. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clin Pharmacol Ther 2012;91:829-37
   PubMed Web of Science ®Google Scholar
• Bergmeijer TO, Janssen PWA, Schipper JC, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-rationale and design of the patient outcome after primary PCI (POPular) genetics study. Am Heart J 2014;168:16-22
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 Genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014;7:895-902
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
   PubMed Web of Science ®Google Scholar
• Aradi D, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 2013;167:2140-8
   PubMed Web of Science ®Google Scholar
• Dridi NP, Johansson PI, Clemmensen P, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response–the TAILOR (thrombocytes and individualization of oral antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 2014;25:506-12
   PubMed Web of Science ®Google Scholar
• Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther 2014;96:482-9
   PubMed Web of Science ®Google Scholar